<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900183</url>
  </required_header>
  <id_info>
    <org_study_id>ARCAAT2001</org_study_id>
    <secondary_id>2016-000917-59</secondary_id>
    <nct_id>NCT02900183</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels</brief_title>
  <official_title>An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as Evidenced by Changes in Liver Biopsy in Patients With Alpha-1 Antitrypsin Deficiency (AATD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple&#xD;
      doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post&#xD;
      last dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, multi-dose study to evaluate the safety, tolerability and effect on&#xD;
      intrahepatic and circulating Alpha-1 Antitrypsin (AAT) levels of ARC-AAT Injection,&#xD;
      administered intravenously. Participants who have signed an Institutional Review Board/Ethics&#xD;
      Committee (IRB/EC) approved informed consent form and met all of the protocol eligibility&#xD;
      criteria will receive multiple intravenous doses (7 total doses administered every 28 days)&#xD;
      of ARC-AAT Injection. Patients previously, currently or never receiving AAT augmentation&#xD;
      therapy are acceptable for enrollment. All subjects will require a pre-dose biopsy and a&#xD;
      post-dose biopsy completed after the last dose or at early termination as applicable. For&#xD;
      each participant the duration of the study clinic visits is approximately 49 weeks, from the&#xD;
      beginning of the Screening period to the Day 287 End-of-Study (EOS) visit.&#xD;
&#xD;
      The following evaluations will be performed at regular intervals throughout the study:&#xD;
      medical history, physical examinations, bee venom allergy blood test, vital sign measurements&#xD;
      (blood pressure, temperature, heart rate, respiratory rate), weight, adverse events&#xD;
      monitoring, electrocardiograms (ECGs), pregnancy tests (females), concurrent medication&#xD;
      evaluation, pulmonary function testing, clinical laboratory tests including hematology,&#xD;
      coagulation, chemistry, FibroTest, anti-drug antibodies, drug screens, serum AAT levels,&#xD;
      liver biopsy, FibroScan, and urinalysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company decision to not initiate trial&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and frequency of adverse events as a measure of safety and tolerability of multiple doses of ARC-AAT Injection</measure>
    <time_frame>Baseline through Day 287 End-of Study Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in circulating serum levels of alpha-1 antitrypsin</measure>
    <time_frame>Baseline through Day 287 End-of Study Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>ARC-AAT Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-AAT Injection</intervention_name>
    <description>RNA interference (RNAi)-based, liver-targeted therapeutic</description>
    <arm_group_label>ARC-AAT Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-nursing female patients 18-75 years of age, inclusive, at the time of&#xD;
             Screening&#xD;
&#xD;
          -  Previous diagnosis of PiZZ genotype Alpha-1 Antitrypsin Deficiency (AATD)&#xD;
&#xD;
          -  Non-smoker (not a daily cigarette smoker) for at least three years with current&#xD;
             non-smoking status confirmed by urine cotinine at screening.&#xD;
&#xD;
          -  Highly effective, double barrier contraception (both male and female partners) during&#xD;
             the study and for 3 months following the last dose of ARC-AAT Injection&#xD;
&#xD;
          -  Suitable venous access for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of hepatic fibrosis from a cause other than AATD&#xD;
&#xD;
          -  History of poorly controlled autoimmune disease, or any history of autoimmune&#xD;
             hepatitis&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Seropositive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV)&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of cardiac rhythm disturbances&#xD;
&#xD;
          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe&#xD;
             cardiovascular disease, transient ischemic attack (TIA) or cerebrovascular accident&#xD;
             (CVA) within 6 months prior to study entry&#xD;
&#xD;
          -  History of malignancy within the last 2 years except for adequately treated basal cell&#xD;
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical&#xD;
             cancer&#xD;
&#xD;
          -  History of major surgery within 1 month of Screening&#xD;
&#xD;
          -  Regular use of alcohol within one month prior to the Screening visit&#xD;
&#xD;
          -  Use of illicit drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year&#xD;
             prior to Screening or positive urine drug screen at Screening&#xD;
&#xD;
          -  Use of an investigational agent or device within 30 days prior to dosing or current&#xD;
             participation in an investigational study involving a therapeutic intervention&#xD;
&#xD;
          -  Any clinically significant history/presence of an uncontrolled systemic disease&#xD;
&#xD;
          -  Blood donation (â‰¥500 mL) within 7 days prior to study treatment administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inspiration Research Limited</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo Foundation, University of Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital, Department of Gastroenterology</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

